Covetrus, Inc. engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded on April 13, 2018 and is headquartered in Melville, NY.
Industry, Sector and Symbol
Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorComputer and Technology
CIKN/A
Phone888-280-2221
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.78 billion
Profitability
Miscellaneous
Employees5,000
Next Earnings Date2/11/2020 (Estimated)
OptionableNot Optionable
Covetrus (NASDAQ:CVET) Frequently Asked Questions
What is Covetrus' stock symbol?
Covetrus trades on the NASDAQ under the ticker symbol "CVET."
How were Covetrus' earnings last quarter?
Covetrus Inc (NASDAQ:CVET) released its quarterly earnings data on Tuesday, November, 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.08 by $0.09. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $963.69 million. Covetrus had a positive return on equity of 4.26% and a negative net margin of 23.15%. The company's revenue was up 10.3% on a year-over-year basis. View Covetrus' Earnings History.
When is Covetrus' next earnings date?
What price target have analysts set for CVET?
8 brokerages have issued twelve-month price targets for Covetrus' shares. Their forecasts range from $11.00 to $21.00. On average, they expect Covetrus' share price to reach $15.25 in the next twelve months. This suggests a possible upside of 17.0% from the stock's current price. View Analyst Price Targets for Covetrus.
What is the consensus analysts' recommendation for Covetrus?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Covetrus.
Has Covetrus been receiving favorable news coverage?
Media headlines about CVET stock have trended neutral this week, according to InfoTrie. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Covetrus earned a coverage optimism score of 0.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Covetrus.
Are investors shorting Covetrus?
Covetrus saw a decline in short interest in the month of November. As of November 29th, there was short interest totalling 13,190,000 shares, a decline of 7.7% from the November 14th total of 14,290,000 shares. Based on an average trading volume of 2,342,600 shares, the days-to-cover ratio is currently 5.6 days. Currently, 13.6% of the company's stock are sold short. View Covetrus' Current Options Chain.
Who are some of Covetrus' key competitors?
What other stocks do shareholders of Covetrus own?
Who are Covetrus' key executives?
Covetrus' management team includes the folowing people:
- Benjamin J. Shaw, President, Chief Executive Officer & Director
- Christine Tomlinson Komola, Chief Financial Officer & Executive Vice President
- Matthew Leonard, Executive VP & President-North America
- Jim Young, Chief Human Resources Officer & Senior VP
- Erin Powers Brennan, Secretary, Senior Vice President & General Counsel
Who are Covetrus' major shareholders?
Covetrus' stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (2.49%), First Trust Advisors LP (1.41%), Great West Life Assurance Co. Can (0.87%), Alecta Pensionsforsakring Omsesidigt (0.56%), Gabelli Funds LLC (0.38%) and Lumbard & Kellner LLC (0.27%). Company insiders that own Covetrus stock include Benjamin Shaw, Betsy S Atkins, David Christopher Dollar, Erin Powers Brennan and Timothy Ludlow. View Institutional Ownership Trends for Covetrus.
Which major investors are buying Covetrus stock?
CVET stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, First Trust Advisors LP, Great West Life Assurance Co. Can, Alecta Pensionsforsakring Omsesidigt, Gabelli Funds LLC, Lumbard & Kellner LLC, TimesSquare Capital Management LLC and Rhumbline Advisers. Company insiders that have bought Covetrus stock in the last two years include Benjamin Shaw and Erin Powers Brennan. View Insider Buying and Selling for Covetrus.
How do I buy shares of Covetrus?
Shares of CVET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Covetrus' stock price today?
One share of CVET stock can currently be purchased for approximately $13.03.
How big of a company is Covetrus?
What is Covetrus' official website?
How can I contact Covetrus?
Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The company can be reached via phone at 888-280-2221 or via email at [email protected]
MarketBeat Community Rating for Covetrus (NASDAQ CVET)
MarketBeat's community ratings are surveys of what our community members think about Covetrus and other stocks. Vote "Outperform" if you believe CVET will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVET will underperform the S&P 500 over the long term. You may vote once every thirty days.
